Paper19251630
Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis.
Hugonnet JE and 4 others. Science, 2009. Cited by 391 papers, by iCite.
Cite this record
ConductScience Library. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Papers, record 19251630. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19251630
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibiotics, Antitubercular | Major topic |
| Clavulanic Acid | Major topic |
| Drug Resistance, Multiple, Bacterial | Major topic |
| Extensively Drug-Resistant Tuberculosis | Major topic |
| Mycobacterium tuberculosis | Major topic |
| Thienamycins | Major topic |
| beta-Lactamases | Major topic |
| Acylation | |
| Catalytic Domain | |
| Crystallography, X-Ray | |
| Drug Combinations | |
| Enzyme Inhibitors | |
| Humans | |
| Kinetics | |
| Mass Spectrometry | |
| Meropenem | |
| Microbial Sensitivity Tests | |
| beta-Lactamase Inhibitors |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Z01 AI000693 | Intramural NIH HHS | United States | ZIAAI000693 | PubMed and NIH | NIH RePORTER |
| Wellcome Trust | United Kingdom | PubMed | PubMed | ||
| AI33696 | NIAID NIH HHS | United States | R01AI033696 | PubMed and NIH | NIH RePORTER |
| ZIAAI000783 | NIH | NIH RePORTER |
References17
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18408028 | The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation. | J Bacteriol | 2008 | https://conductscience.org/library/papers/18408028 | PubMed |
| 2 | 14977534 | Persistent and dormant tubercle bacilli and latent tuberculosis. | Front Biosci | 2004 | https://conductscience.org/library/papers/14977534 | PubMed |
| 3 | 7049231 | Inhibition of the RTEM beta-lactamase from Escherichia coli. Interaction of the enzyme with derivatives of olivanic acid. | Biochemistry | 1982 | https://conductscience.org/library/papers/7049231 | PubMed |
| 4 | 9624510 | Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates. | Antimicrob Agents Chemother | 1998 | https://conductscience.org/library/papers/9624510 | PubMed |
| 5 | 8675308 | An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. | Infect Immun | 1996 | https://conductscience.org/library/papers/8675308 | PubMed |
| 6 | 9634230 | Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. | Nature | 1998 | https://conductscience.org/library/papers/9634230 | PubMed |
| 7 | 6416162 | In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 1983 | https://conductscience.org/library/papers/6416162 | PubMed |
| 8 | 15081094 | The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis. | Int J Antimicrob Agents | 2004 | https://conductscience.org/library/papers/15081094 | PubMed |
| 9 | 15608701 | Tuberculosis - metabolism and respiration in the absence of growth. | Nat Rev Microbiol | 2005 | https://conductscience.org/library/papers/15608701 | PubMed |
| 10 | 17084757 | Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. | Lancet | 2006 | https://conductscience.org/library/papers/17084757 | PubMed |
| 11 | 16870770 | Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics. | Antimicrob Agents Chemother | 2006 | https://conductscience.org/library/papers/16870770 | PubMed |
| 12 | 15699201 | Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to beta-lactam antibiotics. | Microbiology (Reading) | 2005 | https://conductscience.org/library/papers/15699201 | PubMed |
| 13 | 18422342 | Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate. | Biochemistry | 2008 | https://conductscience.org/library/papers/18422342 | PubMed |
| 14 | 10549364 | How beta-lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention. | Adv Exp Med Biol | 1998 | https://conductscience.org/library/papers/10549364 | PubMed |
| 15 | 9564467 | Activity of amoxicillin/clavulanate in patients with tuberculosis. | Clin Infect Dis | 1998 | https://conductscience.org/library/papers/9564467 | PubMed |
| 16 | 17915954 | Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. | Biochemistry | 2007 | https://conductscience.org/library/papers/17915954 | PubMed |
| 17 | 14670344 | M. tuberculosis persistence, latency, and drug tolerance. | Tuberculosis (Edinb) | 2004 | https://conductscience.org/library/papers/14670344 | PubMed |
Cited by254
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 391 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42337014 | Genetic interference of distinctive Mycobacterium tuberculosis peptidoglycan modifications enhances β-lactam susceptibility and reveals expression-sensitive host immune dynamics. | Sci Rep | 2026 | https://conductscience.org/library/papers/42337014 | PubMed |
| 42170912 | Peptide Mimetic Platform for Activity Profiling of Mycobacterial l,d-Transpeptidases. | Biochemistry | 2026 | https://conductscience.org/library/papers/42170912 | PubMed |
| 42030160 | The mycobacterial ATP burst is a lysis artifact and serves as an assay for drug-induced cell wall damage. | Cell Rep | 2026 | https://conductscience.org/library/papers/42030160 | PubMed |
| 41925602 | A historical budget impact and expenditure analysis of meropenem and clavulanate-based treatment for adults with XDR-TB at a specialised TB hospital in South Africa. | S Afr Fam Pract (2004) | 2026 | https://conductscience.org/library/papers/41925602 | PubMed |
| 41676486 | Activity Profiling of Mycobacterial L,D-Transpeptidases. | bioRxiv | 2026 | https://conductscience.org/library/papers/41676486 | PubMed |
| 41463713 | Peptidoglycan LD-Transpeptidases. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/41463713 | PubMed |
| 41354769 | Effects of CwlM, a peptidoglycan synthesis regulator, on beta-lactam tolerance and host-pathogen interactions. | BMC Microbiol | 2025 | https://conductscience.org/library/papers/41354769 | PubMed |
| 41279242 | The mycobacterial ATP burst is a lysis artifact and serves as an assay for drug-induced cell wall damage. | bioRxiv | 2025 | https://conductscience.org/library/papers/41279242 | PubMed |
| 41207943 | Key Proteins and Enzymatic Mechanisms Underlying Drug Resistance in Mycobacterium tuberculosis. | Adv Exp Med Biol | 2026 | https://conductscience.org/library/papers/41207943 | PubMed |
| 41026774 | The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials. | Clin Infect Dis | 2026 | https://conductscience.org/library/papers/41026774 | PubMed |
| 40990707 | New drugs for the management of tuberculosis. | Curr Opin Infect Dis | 2025 | https://conductscience.org/library/papers/40990707 | PubMed |
| 40980328 | Progress of anti-tuberculosis drug targets and novel therapeutic strategies. | Front Microbiol | 2025 | https://conductscience.org/library/papers/40980328 | PubMed |
| 40952390 | Targeting mycobacterial transpeptidases: evaluating the roles of Ldt and PBP inhibition in suppressing Mycobacterium smegmatis. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/40952390 | PubMed |
| 40854973 | Strategic design of a multi-tier database for class A β-lactamase BlaC variants of M. tuberculosis: advancing the fight against antibacterial resistance. | J Antibiot (Tokyo) | 2025 | https://conductscience.org/library/papers/40854973 | PubMed |
| 40657634 | Advances and prospects for treatment strategies of drug-resistant tuberculosis: a review. | GMS Hyg Infect Control | 2025 | https://conductscience.org/library/papers/40657634 | PubMed |
| 40637416 | Exploring β-lactam interactions with DacB1: unraveling optimal therapies for combating drug-resistant Mycobacterium tuberculosis. | mBio | 2025 | https://conductscience.org/library/papers/40637416 | PubMed |
| 40455216 | A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary Tuberculosis. | Clin Infect Dis | 2025 | https://conductscience.org/library/papers/40455216 | PubMed |
| 40428869 | The Adverse Effects of Tuberculosis Treatment: A Comprehensive Literature Review. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/40428869 | PubMed |
| 40295972 | Comparative evaluation of five β-Lactamase inhibitors in combination with β-Lactams against multidrug-resistant Mycobacterium tuberculosis in vitro. | BMC Infect Dis | 2025 | https://conductscience.org/library/papers/40295972 | PubMed |
| 40020440 | Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis. | Drug Resist Updat | 2025 | https://conductscience.org/library/papers/40020440 | PubMed |
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| PDB | 3DWZ |
Source PDB
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19251630
GET https://conductscience.org/api/papers/v1/19251630/cited_by?page=2